Investigational drug · Phase 3
C2402
Also called: Not Applicable
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hypertension, Dyslipidemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "C2402"
First trial start
2024
Dec 2, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "C2402", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypertension
- Dyslipidemia
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "C2402" as an intervention, largest first.
- Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and DyslipidemiaPivotal-lookingRecruiting
JW PharmaceuticalIndustry
NCT06643130 · 162 participants (planned) · Start Dec 2, 2024 · Primary completion Apr 2026
Drug: JW0104+C2402; JW0104+C2403 and 1 more · For: Hypertension; Dyslipidemia
Sites: Seoul, South Korea
JW PharmaceuticalIndustry
NCT06754943 · 60 participants · Start Jan 17, 2025 · Primary completion Mar 24, 2025
Drug: Treatment A_Period 1; Treatment B_Period 2 and 6 more · For: Healthy
Sites: Anyang-si, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Reconsidering the Mechanism of Proton Pump Inhibitor-Associated Fundic Gland Polyps: Absence of Re-enlargement during Potassium-Competitive Acid Blocker Therapy.
Misumi Y, Marumo T, Ban S, et al. · DEN Open 2027
- Post-Endoscopic Retrograde Cholangiopancreatography Bleeding After Endoscopic Stone Removal in Dialysis Patients: A Multicenter Retrospective Study.
Nishimura M, Miwa H, Kaneko T, et al. · DEN Open 2027
- Multiplex methylation marker analysis for ctDNA detection in liquid biopsies from anal cancer patients: an HPV-independent approach.
Kahns S, Canto LMD, Stokkebro LE, et al. · Clin Chim Acta 2027
- The Rural Ecological Framework of Intimate Partner Violence (RE-IPV): Social-Ecological Factors and Constrained Agency Among Rural Women.
Kimber F, Abusbaitan H, Munala L, et al. · Nurs Inq 2027
- Explainable artificial intelligence in clinical decision support systems: a systematic review of techniques, clinical applications, evaluation, and future directions.
Zandkarimi E, Ghorbanzadeh K · Int J Med Inform 2027
- Beyond removal of total petroleum hydrocarbons: An evidence-tiered mass-balance framework and critical review of priority and emerging contaminants in oily-sludge valorization.
Yu T, Qu K, Hui K, et al. · Waste Manag 2027
Also in development for Hypertension
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
- VCT220CX11Phase 35 trials
Vincentage Pharma Co., Ltd · Obesity, Type 2 Diabetes Mellitus (DM), Hypertension
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- ZilebesiranALN-AGT01Phase 34 trials
Alnylam Pharmaceuticals · Hypertension, High Cardiovascular Risk, High Risk Cardiovascular Disease
- ClazakizumabLY5724886, CSL300Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity
- DWC202314Phase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.